Magnetic resonance imaging measurements of left atrial scarring in patients with atrial fibrillation (AF) are associated with poor outcomes of first AF catheter ablation, according to a study published in the Feb. 5 issue of the Journal of the American Medical Association.
Many patients who should receive the anticoagulant warfarin according to guidelines do not, a new study finds.
The FDA mandated a new safety warning for the heart rhythm drug Multaq after studies showed that it doubled the risk of heart-related complications in patients with permanent atrial fibrillation.
The FDA has approved dabigatran, an oral direct thrombin inhibitor that offers key advantages over warfarin for patients at risk for stroke.
The oral blood thinner apixaban prevents stroke in patients with atrial fibrillation who are not suitable candidates for treatment with warfarin.
Medtronic, Inc., has announced results of a clinical trial of its ablation system for patients with persistent atrial fibrillation.
Half of patients with atrial fibrillation either deny or do not know they are at increased risk of stroke, a recent American Heart Association survey finds.